Norma Lynn Fox

3.0k total citations
33 papers, 2.3k citations indexed

About

Norma Lynn Fox is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Norma Lynn Fox has authored 33 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Cardiology and Cardiovascular Medicine and 7 papers in Surgery. Recurrent topics in Norma Lynn Fox's work include Cell death mechanisms and regulation (10 papers), Systemic Lupus Erythematosus Research (7 papers) and Coronary Interventions and Diagnostics (5 papers). Norma Lynn Fox is often cited by papers focused on Cell death mechanisms and regulation (10 papers), Systemic Lupus Erythematosus Research (7 papers) and Coronary Interventions and Diagnostics (5 papers). Norma Lynn Fox collaborates with scholars based in United States, United Kingdom and Canada. Norma Lynn Fox's co-authors include J. Richard Hebel, Mary Sexton, A. Corey, David A. Roth, Wendy Halpern, James Groark, Margaret von Mehren, David Gordon, Anne E. Hammer and Roger B. Cohen and has published in prestigious journals such as Circulation, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Norma Lynn Fox

32 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Norma Lynn Fox United States	21	881	596	380	357	354	33	2.3k
S Richards United Kingdom	25	455 0.5×	335 0.6×	352 0.9×	195 0.5×	287 0.8×	40	3.5k
Lucía Mercedes Mauro United States	20	1.4k 1.6×	722 1.2×	229 0.6×	71 0.2×	157 0.4×	44	2.7k
Anand P. Chokkalingam United States	29	918 1.0×	310 0.5×	335 0.9×	61 0.2×	311 0.9×	79	2.9k
Harshal Nandurkar Australia	33	982 1.1×	721 1.2×	463 1.2×	85 0.2×	87 0.2×	118	3.6k
Paul van der Valk Netherlands	34	1.1k 1.2×	310 0.5×	1.2k 3.1×	92 0.3×	111 0.3×	118	3.6k
Zhen Zeng China	24	419 0.5×	560 0.9×	624 1.6×	70 0.2×	301 0.9×	77	2.2k
George Bayliss United States	25	833 0.9×	658 1.1×	207 0.5×	64 0.2×	399 1.1×	70	2.3k
Lori Styles United States	41	493 0.6×	488 0.8×	161 0.4×	157 0.4×	136 0.4×	95	4.8k
A. H. Zwinderman Netherlands	26	263 0.3×	581 1.0×	253 0.7×	383 1.1×	1.8k 5.1×	48	4.0k
Nicole L. Glazer United States	22	1.2k 1.3×	212 0.4×	230 0.6×	132 0.4×	69 0.2×	31	3.1k

Countries citing papers authored by Norma Lynn Fox

Since Specialization

Citations

This map shows the geographic impact of Norma Lynn Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norma Lynn Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norma Lynn Fox more than expected).

Fields of papers citing papers by Norma Lynn Fox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norma Lynn Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norma Lynn Fox. The network helps show where Norma Lynn Fox may publish in the future.

Co-authorship network of co-authors of Norma Lynn Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Norma Lynn Fox. A scholar is included among the top collaborators of Norma Lynn Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norma Lynn Fox. Norma Lynn Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Manzi, Susan, Jorge Sánchez‐Guerrero, Naoto Yokogawa, et al.. (2025). The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis. Lupus. 34(7). 666–678.

Andorn, Anne C., Barbara R. Haight, Sunita Shinde, et al.. (2020). Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis. Journal of Clinical Psychopharmacology. 40(3). 231–239. 31 indexed citations

Struemper, Herbert, Jane Gilbert, Matthew E. Barton, et al.. (2015). Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects. Clinical Pharmacology in Drug Development. 5(3). 208–215. 26 indexed citations

Pawel, Joachim von, Jimmie H. Harvey, David R. Spigel, et al.. (2014). Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 15(3). 188–196.e2. 81 indexed citations

Mom, Constantijne H., Jaap Verweij, Corina N.A.M. Oldenhuis, et al.. (2009). Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study. Clinical Cancer Research. 15(17). 5584–5590. 85 indexed citations

Fox, Norma Lynn, Robin Humphreys, Troy A. Luster, Jerry L. Klein, & Gilles Gallant. (2009). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy. Expert Opinion on Biological Therapy. 10(1). 1–18. 50 indexed citations

Plummer, Ruth, Gerhardt Attard, Simon Pacey, et al.. (2007). Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers. Clinical Cancer Research. 13(20). 6187–6194. 198 indexed citations

Šikić, Branimir I., Heather A. Wakelee, Margaret von Mehren, et al.. (2007). A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI.. Molecular Cancer Therapeutics. 6. 33 indexed citations

Roach, Charlotte, Jon Askaa, Dennis E. Chenoweth, et al.. (2004). Development of sensitive and specific immunohistochemical assays for pro-apoptotic TRAIL-receptors. Cancer Research. 64. 1145–1145. 6 indexed citations

10.

Fox, Norma Lynn, Byron J. Hoogwerf, Susan M. Czajkowski, et al.. (2004). Quality of Life After Coronary Artery Bypass Graft. CHEST Journal. 126(2). 487–495. 9 indexed citations

11.

Fox, Norma Lynn, et al.. (2002). Thrombopoietin expands hematopoietic stem cells after transplantation. Journal of Clinical Investigation. 110(3). 389–394. 7 indexed citations

12.

Walenga, Jeanine M., Debra Hoppensteadt, Roque Pifarré, et al.. (2001). The Hemostatic Effects of Warfarin Titration in Post CABG Patients in Comparison to Placebo Treatment. Journal of Thrombosis and Thrombolysis. 11(2). 143–149. 2 indexed citations

13.

Fox, Norma Lynn, C. Michael Gibson, Erich Bluhmki, et al.. (2001). Determination of a weight-adjusted dose of TNK–tissue plasminogen activator. American Heart Journal. 141(1). 33–40. 15 indexed citations

14.

Modi, Nishit B., Norma Lynn Fox, P. Tanswell, et al.. (2000). Pharmacokinetics and Pharmacodynamics of Tenecteplase: Results from a Phase II Study in Patients with Acute Myocardial Infarction. The Journal of Clinical Pharmacology. 40(5). 508–515. 41 indexed citations

15.

Werf, Frans Van de, Christopher P. Cannon, Carolyn H. McCabe, et al.. (1999). Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial. American Heart Journal. 137(5). 786–791. 111 indexed citations

16.

Gibson, C. Michael, Christopher P. Cannon, Sabina A. Murphy, et al.. (1999). Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. The American Journal of Cardiology. 84(9). 976–980. 26 indexed citations

17.

Sexton, Mary, Norma Lynn Fox, & J. Richard Hebel. (1990). Prenatal Exposure to Tobacco: II Effects on Cognitive Functioning at Age Three. International Journal of Epidemiology. 19(1). 72–77. 158 indexed citations

18.

Fox, Norma Lynn, Mary Sexton, & J. Richard Hebel. (1990). Prenatal Exposure to Tobacco: I. Effects on Physical Growth at Age Three. International Journal of Epidemiology. 19(1). 66–71. 71 indexed citations

19.

Fox, Norma Lynn, et al.. (1989). The reliability of self-reports of smoking and alcohol consumption by pregnant women. Addictive Behaviors. 14(2). 187–195. 39 indexed citations

20.

Hebel, J. Richard, Norma Lynn Fox, & Mary Sexton. (1988). Dose-response of birth weight to various measures of maternal smoking during pregnancy. Journal of Clinical Epidemiology. 41(5). 483–489. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact